LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Book ; Online: Assessment of centralised procurement of medicines in Portugal

    Vogler, Sabine / Habimana, Katharina / Schneider, Peter / Haasis, Manuel Alexander

    summary report

    2021  

    Abstract: This study assesses the performance of centralised procurement of medicines (CPM) in Portugal from a public health perspective and develops policy recommendations. The OECD “Methodology for Assessing Procurement Systems” (MAPS) was applied in an adapted ... ...

    Institution Gesundheit Österreich GmbH
    Europäische Union
    Author's details authors: Sabine Vogler, Katharina Habimana, Eveli Bauer, Peter Schneider, Manuel Alexander Haasis ; project assistant: Monika Schintlmeister ; translation of abstract and executive summary: A. Sousa Coutinho ; funding by the European Union ; EMSPOS - Estrutura de Missão para a Sustentabilidade do Programa Orçamental da Saúde ; Gesundheit Österreich Forschungs- und Planungs GmbH
    Abstract This study assesses the performance of centralised procurement of medicines (CPM) in Portugal from a public health perspective and develops policy recommendations. The OECD “Methodology for Assessing Procurement Systems” (MAPS) was applied in an adapted manner. Information was retrieved from the literature and procurement documents, including bids of selected procurement procedures, and from 42 interviews, thereof 37 on-site interviews with representatives of public authorities, hospitals and regional health administrations, patients and the pharmaceutical industry. Input of procurement experts of five European countries, of Portuguese participants in a stakeholder workshop and of academics in a Delphi survey have contributed to quality-assurance, participation and acceptance. The Shared Services of the Ministry of Health (SPMS) is responsible for performing centralised procurement processes, which comprise both open procedures (Aquisições centralizadas / AC) with one (or two) suppliers and the two-stage processes of framework agreements (Acordos Quadros / AQ). Legal implementation of CPM is compliant with European standards, and the Portuguese system was found to have several strengths. These include its contribution to lower prices (compared to individual purchases) in several (but not all) cases and thus to savings for the public sector, to improved transparency of processes and governance, to more equity in access to medicines across Portugal and to a lower workload for individual procurers. However, weaknesses were also identified. There is a lack of strategy related to CPM and a lack of clarity related to the roles and responsibilities of SPMS and further relevant public institutions and stakeholders with regard to their CPM activities. [...]
    Keywords Public procurement ; pharmaceutical ; evaluation ; access to medicines ; processes ; Portugal
    Subject code 610
    Language English
    Size 1 Online-Ressource (III, 11 Seiten), Diagramme
    Publisher Gesundheit Österreich Forschungs- und Planungs GmbH
    Publishing place Vienna
    Publishing country Austria
    Document type Book ; Online
    Note carried out with funding by the European Union via the Structural Reform Support Programme and in cooperation with the Directorate-General for Structural Reform Support of the European Commission ; Open Access
    HBZ-ID HT020933838
    DOI 10.4126/FRL01-006427711
    Database Repository for Life Sciences

    Kategorien

  2. Book ; Online: Avaliação das aquisições centralizadas dos medicamentos em Portugal

    Vogler, Sabine / Habimana, Katharina / Schneider, Peter / Haasis, Manuel Alexander

    relatório síntese

    2021  

    Abstract: O presente estudo avalia as aquisições centralizadas dos medicamentos (ACM) em Portugal numa perspetiva de saúde pública e desenvolve recomendações políticas. A "Metodologia para a avaliação dos sistemas de aquisição" (MAPS, na sigla em inglês) da OCDE ... ...

    Institution Gesundheit Österreich GmbH
    Europäische Union
    Author's details autores: Sabine Vogler, Katharina Habimana, Eveli Bauer, Peter Schneider, Manuel Alexander Haasis ; assistente do projeto: Monika Schintlmeister ; tradução em português: A. Sousa Coutinho ; com o financiamento da União Europeia ; EMSPOS - Estrutura de Missão para a Sustentabilidade do Programa Orçamental da Saúde ; Gesundheit Österreich Forschungs- und Planungs GmbH
    Abstract O presente estudo avalia as aquisições centralizadas dos medicamentos (ACM) em Portugal numa perspetiva de saúde pública e desenvolve recomendações políticas. A "Metodologia para a avaliação dos sistemas de aquisição" (MAPS, na sigla em inglês) da OCDE foi aplicada de forma adaptada. As informações foram obtidas da literatura e de documentos de aquisições, incluindo propostas de procedimentos de aquisição selecionados, e de 42 entrevistas, das quais 37 realizadas no local com representantes de autoridades públicas, hospitais e administrações regionais de saúde, pacientes e indústria farmacêutica. O input de especialistas em aquisições de 5 países europeus, de participantes portugueses num seminário de pessoas interessadas e de académicos num inquérito Delphi contribuiu para a garantia de qualidade, participação e aceitação. A Serviços Partilhados do Ministério da Saúde (SPMS) é responsável pela realização dos processos de aquisições centralizadas, os quais compreendem procedimentos abertos (Aquisições centralizadas / AC) com um (ou dois) fornecedores e processos de Acordos Quadros / AQ) de duas fases. A aplicação jurídica das ACM está em conformidade com as normas europeias, e concluiu-se que o sistema português tem várias forças. Trata-se nomeadamente da sua contribuição para preços mais baixos (em comparação com aquisições individuais) em vários casos (mas não todos) e, por conseguinte, de poupanças para o sector público, de uma maior transparência dos processos e da governação, de uma maior equidade no acesso aos medicamentos em Portugal, e de um menor volume de trabalho para os adquirentes individuais. Contudo, foram também identificadas as fraquezas. [...]
    Keywords Aquisições públicas ; farmacêutica ; avaliação ; acesso aos medicamentos ; processos ; Portugal
    Subject code 610
    Language Portuguese
    Size 1 Online-Ressource (III, 12 Seiten), Diagramme
    Publisher Gesundheit Österreich Forschungs- und Planungs GmbH
    Publishing place Viena
    Publishing country Austria
    Document type Book ; Online
    Note realizado com o financiamento da União Europeia através do Programa de Apoio às Reformas Estruturais e em cooperação com a Direção-Geral do Apoio às Reformas Estruturais da Comissão Europeia ; Open Access
    HBZ-ID HT020934073
    DOI 10.4126/FRL01-006427713
    Database Repository for Life Sciences

    Kategorien

  3. Book ; Online: Assessment of centralised procurement of medicines in Portugal

    Vogler, Sabine / Habimana, Katharina / Schneider, Peter / Haasis, Manuel Alexander

    full report

    2021  

    Abstract: This study assesses the performance of centralised procurement of medicines (CPM) in Portugal from a public health perspective and develops policy recommendations. The OECD “Methodology for Assessing Procurement Systems” (MAPS) was applied in an adapted ... ...

    Institution Gesundheit Österreich GmbH
    Europäische Union
    Author's details authors: Sabine Vogler, Katharina Habimana, Eveli Bauer, Peter Schneider, Manuel Alexander Haasis ; project assistant: Monika Schintlmeister ; translation of abstract and executive summary: A. Sousa Coutinho ; funding by the European Union ; Gesundheit Österreich Forschungs- und Planungs GmbH
    Abstract This study assesses the performance of centralised procurement of medicines (CPM) in Portugal from a public health perspective and develops policy recommendations. The OECD “Methodology for Assessing Procurement Systems” (MAPS) was applied in an adapted manner. Information was retrieved from the literature and procurement documents, including bids of selected procurement procedures, and from 42 interviews, thereof 37 on-site interviews with representatives of public authorities, hospitals and regional health administrations, patients and the pharmaceutical industry. Input of procurement experts of five European countries, of Portuguese participants in a stakeholder workshop and of academics in a Delphi survey have contributed to quality-assurance, participation and acceptance. The Shared Services of the Ministry of Health (SPMS) is responsible for performing centralised procurement processes, which comprise both open procedures (Aquisições centralizadas / AC) with one (or two) suppliers and the two-stage processes of framework agreements (Acordos Quadros / AQ). Legal implementation of CPM is compliant with European standards, and the Portuguese system was found to have several strengths. These include its contribution to lower prices (compared to individual purchases) in several (but not all) cases and thus to savings for the public sector, to improved transparency of processes and governance, to more equity in access to medicines across Portugal and to a lower workload for individual procurers. However, weaknesses were also identified. There is a lack of strategy related to CPM and a lack of clarity related to the roles and responsibilities of SPMS and further relevant public institutions and stakeholders with regard to their CPM activities. [...]
    Keywords Public procurement ; pharmaceutical ; evaluation ; access to medicines ; processes ; Portugal
    Subject code 610
    Language English
    Size 1 Online-Ressource (XXV, 58, LXIV Seiten), Diagramme
    Publisher Gesundheit Österreich Forschungs- und Planungs GmbH
    Publishing place Vienna
    Publishing country Austria
    Document type Book ; Online
    Note carried out with funding by the European Union via the Structural Reform Support Programme and in cooperation with the Directorate-General for Structural Reform Support of the European Commission ; inhaltliche Zusammenfassung in portugiesischer und englischer Sprache ; Open Access
    HBZ-ID HT020933833
    DOI 10.4126/FRL01-006427709
    Database Repository for Life Sciences

    Kategorien

  4. Book ; Online: Novel policy options for reimbursement, pricing and procurement of AMR health technologies

    Vogler, Sabine / Habimana, Katharina / Fischer, Stefan / Haasis, Manuel Alexander

    final report

    2021  

    Abstract: Antimicrobial resistance (AMR) is a global health threat. A key pillar in the multi-faceted approach to tackle AMR includes the development and commercialisation of novel antibiotics to replace those to which patients are increasingly becoming resistant. ...

    Institution Gesundheit Österreich GmbH
    Author's details authors: Sabine Vogler, Katharina Habimana, Stefan Fischer, Manuel Alexander Haasis ; project assistant: Monika Schintlmeister ; commissioned by the Global AMR R&D Hub ; Gesundheit Österreich Forschungs- und Planungs GmbH
    Abstract Antimicrobial resistance (AMR) is a global health threat. A key pillar in the multi-faceted approach to tackle AMR includes the development and commercialisation of novel antibiotics to replace those to which patients are increasingly becoming resistant. Another approach is focused on diagnostics, which, among others, help decide whether or not the prescription of an antibiotic is required, thus reducing antibiotic consumption. Medicines and medical devices, hereinafter referred to as health technologies, usually enter the market of a country after the public authority has decided whether, and to what extent, the cost of the specific health technology will be paid for by the public payer. Linked to these reimbursement and procurement decisions, the price of the health technologies can also be determined by authorities. AMR health technologies have special characteristics such as a dearth of data and evidence, a value to society higher than added therapeutic benefit, and comparably low prices of antibiotics compared to diagnostics. These considerations are not yet well captured by the current standard policies on reimbursement, pricing and procurement. There is a need for a more finely tuned set of specific policy options. Against this backdrop, the study aimed to identify specific policy options in reimbursement, pricing and procurement that are able to incentivise production and market entry of AMR health technologies (novel antibiotics and diagnostics). Included are examples of national policies already in place for AMR health technologies as well as for health technologies with similar characteristics.
    Subject code 610
    Language English
    Size 1 Online-Ressource (XVIII, 171 Seiten), Diagramme
    Publisher Gesundheit Österreich Forschungs- und Planungs GmbH
    Publishing place Wien
    Publishing country Austria
    Document type Book ; Online
    Note Open Access
    HBZ-ID HT020934113
    DOI 10.4126/FRL01-006427715
    Database Repository for Life Sciences

    Kategorien

  5. Article ; Online: Purchasing medicines for the public sector: Evaluation of the performance of centralised procurement in Portugal.

    Vogler, Sabine / Habimana, Katharina / Haasis, Manuel Alexander

    The International journal of health planning and management

    2022  Volume 37, Issue 4, Page(s) 2007–2031

    Abstract: Objective: The study aimed to evaluate centralised procurement of medicines (CPM) in Portugal.: Methods: Data were collected through different methods, including a review of the literature and (procurement) documents and an analysis of selected bids. ...

    Abstract Objective: The study aimed to evaluate centralised procurement of medicines (CPM) in Portugal.
    Methods: Data were collected through different methods, including a review of the literature and (procurement) documents and an analysis of selected bids. Thirty-seven face-to-face interviews with representatives of public authorities, users (hospitals and regional health administrations), patient associations and pharmaceutical industry were held in Portugal in Q1/2020.
    Results: CPM has contributed to improved transparency in processes and governance, to increased equity in access to medicines across the country and to lower workload for some users. The findings of the impact on medicine prices and availability are mixed. The benefits of CPM are undermined by some gaps: Lengthy, bureaucratic processes have resulted in delayed availability of medicines at the beginning of a year and in coping strategies of hospitals such as parallel individual procurements. The list of active ingredients under CPM has not been updated since 2016. The procurement agency does not routinely perform market consultations. Key performance indicators for CPM are lacking.
    Conclusions: Portuguese policy-makers are urged to develop an updated procurement strategy to provide guidance and clarity on the objectives of CPM, the role of the procurement agency and further authorities and key performance indicators.
    MeSH term(s) Drug Costs ; Health Services Accessibility ; Humans ; Portugal ; Public Sector
    Language English
    Publishing date 2022-02-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 632786-2
    ISSN 1099-1751 ; 0749-6753
    ISSN (online) 1099-1751
    ISSN 0749-6753
    DOI 10.1002/hpm.3444
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Innovations in pharmaceutical policies and learnings for sustainable access to affordable medicines.

    Vogler, Sabine / Zimmermann, Nina / Haasis, Manuel Alexander / Knoll, Verena / Espin, Jaime / Mantel-Teeuwisse, Aukje K / Panteli, Dimitra / Suleman, Fatima / Wirtz, Veronika J / Babar, Zaheer-Ud-Din

    Journal of pharmaceutical policy and practice

    2024  Volume 17, Issue Suppl 1, Page(s) 2335492

    Abstract: Sustainable access to affordable medicines remains a public health issue globally, including for high-income countries. To foster the debate on avenues for the future, the fifth PPRI Conference held in Vienna on 25 and 26 April 2024 will offer a forum ... ...

    Abstract Sustainable access to affordable medicines remains a public health issue globally, including for high-income countries. To foster the debate on avenues for the future, the fifth PPRI Conference held in Vienna on 25 and 26 April 2024 will offer a forum for the debate on innovating pharmaceutical policymaking to develop and implement futureproof policy options, which are able to address current and future challenges. The Conference invites a broad audience of stakeholders, including researchers, policymakers, payers, patients, industry and health professionals. The conference topics are organised in three strands: Strand 1 on 'Local challenges, global learnings' aims to contribute to lively discussions on the implementation of pharmaceutical policies across the globe. Best-practice examples will be presented, supplemented by case studies of less effective policies which can offer rich learnings. Strand 2 on 'Strengthening the evidence base' is the place for presentations and discussions on topics such as health technology assessments, managed entry agreements and real-world data. Strand 3 'Futureproofing pharmaceutical policies' is particularly dedicated to explore innovation in policymaking to achieve sustainable access to affordable medicines.
    Language English
    Publishing date 2024-04-24
    Publishing country England
    Document type Editorial
    ZDB-ID 2734772-2
    ISSN 2052-3211
    ISSN 2052-3211
    DOI 10.1080/20523211.2024.2335492
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer?

    Suwanthawornkul, Thanthima / Praditsitthikorn, Naiyana / Kulpeng, Wantanee / Haasis, Manuel Alexander / Guerrero, Anna Melissa / Teerawattananon, Yot

    Cost effectiveness and resource allocation : C/E

    2018  Volume 16, Page(s) 7

    Abstract: Background: Many economic evaluations ignore economies of scale in their cost estimation, which means that cost parameters are assumed to have a linear relationship with the level of production. Economies of scale is the situation when the average total ...

    Abstract Background: Many economic evaluations ignore economies of scale in their cost estimation, which means that cost parameters are assumed to have a linear relationship with the level of production. Economies of scale is the situation when the average total cost of producing a product decreases with increasing volume caused by reducing the variable costs due to more efficient operation. This study investigates the significance of applying the economies of scale concept: the saving in costs gained by an increased level of production in economic evaluation of pneumococcal conjugate vaccines (PCV) and human papillomavirus (HPV) vaccinations.
    Methods: The fixed and variable costs of providing partial (20% coverage) and universal (100% coverage) vaccination programs in the Philippines were estimated using various methods, including costs of conducting questionnaire survey, focus-group discussion, and analysis of secondary data. Costing parameters were utilised as inputs for the two economic evaluation models for PCV and HPV. Incremental cost-effectiveness ratios (ICERs) and 5-year budget impacts with and without applying economies of scale to the costing parameters for partial and universal coverage were compared in order to determine the effect of these different costing approaches.
    Results: The program costs of the partial coverage for the two immunisation programs were not very different when applying and not applying the economies of scale concept. Nevertheless, the program costs for universal coverage were 0.26 and 0.32 times lower when applying economies of scale compared to not applying economies of scale for the pneumococcal and human papillomavirus vaccinations, respectively. ICERs varied by up to 98% for pneumococcal vaccinations, whereas the change in ICERs in the human papillomavirus vaccination depended on both the costs of cervical cancer screening and the vaccination program. This results in a significant difference in the 5-year budget impact, accounting for 30 and 40% of reduction in the 5-year budget impact for the pneumococcal and human papillomavirus vaccination programs.
    Conclusions: This study demonstrated the feasibility and importance of applying economies of scale in the cost estimation in economic evaluation, which would lead to different conclusions in terms of value for money regarding the interventions, particularly with population-wide interventions such as vaccination programs. The economies of scale approach to costing is recommended for the creation of methodological guidelines for conducting economic evaluations.
    Language English
    Publishing date 2018-02-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2119372-1
    ISSN 1478-7547
    ISSN 1478-7547
    DOI 10.1186/s12962-018-0087-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.

    Haasis, Manuel Alexander / Ceria, Joyce Anne / Kulpeng, Wantanee / Teerawattananon, Yot / Alejandria, Marissa

    PloS one

    2015  Volume 10, Issue 7, Page(s) e0131156

    Abstract: Objectives: The objective of this study is to assess the value for money of introducing pneumococcal conjugate vaccines as part of the immunization program in a lower-middle income country, the Philippines, which is not eligible for GAVI support and ... ...

    Abstract Objectives: The objective of this study is to assess the value for money of introducing pneumococcal conjugate vaccines as part of the immunization program in a lower-middle income country, the Philippines, which is not eligible for GAVI support and lower vaccine prices. It also includes the newest clinical evidence evaluating the efficacy of PCV10, which is lacking in other previous studies.
    Methods: A cost-utility analysis was conducted. A Markov simulation model was constructed to examine the costs and consequences of PCV10 and PCV13 against the current scenario of no PCV vaccination for a lifetime horizon. A health system perspective was employed to explore different funding schemes, which include universal or partial vaccination coverage subsidized by the government. Results were presented as incremental cost-effectiveness ratios (ICERs) in Philippine peso (Php) per QALY gained (1 USD = 44.20 Php). Probabilistic sensitivity analysis was performed to determine the impact of parameter uncertainty.
    Results: With universal vaccination at a cost per dose of Php 624 for PCV10 and Php 700 for PCV13, both PCVs are cost-effective compared to no vaccination given the ceiling threshold of Php 120,000 per QALY gained, yielding ICERs of Php 68,182 and Php 54,510 for PCV10 and PCV13, respectively. Partial vaccination of 25% of the birth cohort resulted in significantly higher ICER values (Php 112,640 for PCV10 and Php 84,654 for PCV13) due to loss of herd protection. The budget impact analysis reveals that universal vaccination would cost Php 3.87 billion to 4.34 billion per annual, or 1.6 to 1.8 times the budget of the current national vaccination program.
    Conclusion: The inclusion of PCV in the national immunization program is recommended. PCV13 achieved better value for money compared to PCV10. However, the affordability and sustainability of PCV implementation over the long-term should be considered by decision makers.
    MeSH term(s) Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Cost-Benefit Analysis ; Female ; Financing, Government ; Humans ; Immunization Programs/economics ; Income ; Infant ; Infant, Newborn ; Male ; Markov Chains ; Middle Aged ; Philippines ; Pneumococcal Vaccines/administration & dosage ; Pneumococcal Vaccines/economics ; Pneumonia, Pneumococcal/immunology ; Pneumonia, Pneumococcal/microbiology ; Pneumonia, Pneumococcal/prevention & control ; Streptococcus pneumoniae/drug effects ; Streptococcus pneumoniae/immunology ; Vaccination/economics ; Vaccines, Conjugate
    Chemical Substances 10-valent pneumococcal conjugate vaccine ; 13-valent pneumococcal vaccine ; Pneumococcal Vaccines ; Vaccines, Conjugate
    Language English
    Publishing date 2015-07-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0131156
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top